Ardelyx, Inc. Reports Employment Inducement Grants
27 Julho 2023 - 5:05PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that on July 25, 2023, the compensation committee
of the company’s board of directors granted three new non-executive
employees options to purchase an aggregate of 100,216 shares of the
company’s common stock, and granted four new non-executive
employees an aggregate of 51,000 Restricted Stock Units (RSUs).
Each stock option has an exercise price per share equal to $3.44
per share, which was the closing trading price of the company’s
common stock on the date of grant. The stock options and RSUs were
granted as inducements material to each employee’s decision to
enter into employment with Ardelyx, in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each stock option vests over four years, with 25% of the shares
vesting on the first anniversary of the employee’s first date of
employment, and the remaining 75% of shares vesting monthly
thereafter. Each RSU vests over four years, with 25% vesting on the
first company designated quarterly RSU vest date following the
first anniversary of the employee’s first day of employment and the
remaining 75% of shares vesting quarterly thereafter. Each stock
option has a 10-year term and each option and RSU is subject to the
terms and conditions of the company’s 2016 Employment Commencement
Incentive Plan and the award agreement covering the grant.
About Ardelyx, Inc.Ardelyx was
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs. Ardelyx’s first approved product,
IBSRELA® (tenapanor) is available in the United
States and Canada. Ardelyx is developing
XPHOZAH® (tenapanor), a novel product candidate to control
serum phosphorus in adult patients with chronic kidney disease on
dialysis, which has completed three successful Phase 3
trials. Ardelyx has a Phase 2 potassium lowering
compound, RDX013, for the potential treatment of elevated serum
potassium, or hyperkalemia, a problem among certain patients with
kidney and/or heart disease and an early-stage program in metabolic
acidosis, a serious electrolyte disorder in patients with
CKD. Ardelyx has established agreements with Kyowa Kirin
in Japan, Fosun Pharma in China and Knight
Therapeutics in Canada for the development and
commercialization of tenapanor in their respective territories. For
more information, please visit https://ardelyx.com/ and
connect with us
on Twitter, LinkedIn and Facebook.
Investor and Media Contacts:Caitlin
Lowieclowie@ardelyx.com Kimia Keshtbodkkhestbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024